Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Alaunos Therapeutics (TCRT) over the last 8 years, with Q4 2018 value amounting to $13000.0.

  • Alaunos Therapeutics' Current Deferred Revenue fell 9996.87% to $13000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $13000.0, marking a year-over-year decrease of 9996.87%. This contributed to the annual value of $13000.0 for FY2018, which is 9996.87% down from last year.
  • Per Alaunos Therapeutics' latest filing, its Current Deferred Revenue stood at $13000.0 for Q4 2018, which was down 9996.87% from $49.5 million recorded in Q3 2018.
  • In the past 5 years, Alaunos Therapeutics' Current Deferred Revenue registered a high of $49.5 million during Q3 2018, and its lowest value of $13000.0 during Q4 2018.
  • Over the past 5 years, Alaunos Therapeutics' median Current Deferred Revenue value was $6.4 million (recorded in 2016), while the average stood at $7.9 million.
  • In the last 5 years, Alaunos Therapeutics' Current Deferred Revenue skyrocketed by 68296.57% in 2016 and then tumbled by 9996.87% in 2018.
  • Alaunos Therapeutics' Current Deferred Revenue (Quarter) stood at $1.4 million in 2014, then surged by 404.49% to $6.9 million in 2015, then decreased by 6.88% to $6.4 million in 2016, then surged by 549.55% to $41.5 million in 2017, then tumbled by 99.97% to $13000.0 in 2018.
  • Its Current Deferred Revenue was $13000.0 in Q4 2018, compared to $49.5 million in Q3 2018 and $63000.0 in Q2 2018.